State Institute for Drug Control

The assessment contains information indicated by reports on deliveries of medicinal products to pharmacies, other healthcare facilities and, as far as restricted drugs were concerned, to sellers of restricted drugs. Besides medicinal products with marketing authorisation, medicinal products included in specific treatment programmes and medicinal products without marketing authorisation, delivered to a specific patient on medical prescription, were also assessed.

The information contains solely the data from distributors’ reports. It does not represent the actual consumption of pharmaceuticals by patients, that is, it does not represent the data describing the actual quantities dispensed to patients.

Trend in the Numbers of the Marketed Medicinal Products with Marketing Authorisation

In 2012, the Institute made 703 decisions on marketing authorisation (5,543 codes of the State Institute for Drug Control (SUKL)). During the reference period, marketing authorisation was terminated or cancelled for 12,419 codes.

In total distribution for 45,678 codes (84.48 %) of medicinal products, excluding homeopathics, was not reported during 2012. This means that these medicinal products had valid marketing authorisations but were not marketed.

In the chart, we show the history of the numbers of medicinal products (MP) with marketing authorisation, marketed MPs and reimbursable MPs in 2008 – 2012 (situation as of 1 January 2013).

History of Deliveries of Medicinal Products

This chart shows the history of deliveries of medicinal products for the basic monitored parameters in the years 2008 - 2012.

This chart shows the financial volume and numbers of DDDs according to the zones of business mark-up for the year 2012.

This chart shows the history of the numbers of packs, DDDs and prices of the entities of origin according to the method of dispensation (OTC, OTC with restriction) in total for the years 2008 - 2012.

This chart shows the top 10 MPs distributed to pharmacies and healthcare facilities abroad.

This chart shows the top 10 MPs distributed to other distributors abroad.

*The data on DDDs have been calculated according to the data valid in the given period

In 2012, there were 280.19 million of packs of medicinal products delivered to pharmacies, healthcare facilities and sellers of restricted drugs in the Czech Republic, which represents a decrease by 5.56 % in comparison with the year 2011. The number of defined daily doses reached 878.34 million in 2012, which represents an increase by 1.00 % in comparison with the year 2011. The financial value of the distributed medicinal products is 58.72 billion CZK (in the prices of entities of origin). Thus, as compared with 2011, the financial amount spent on medicinal products slightly decreased (merely by 0.03 %).

It is apparent from the figures shown above that less packs were delivered in terms of quantity but these packs contained larger quantities of daily defined doses. This piece of data may suggest that larger packs of pharmaceuticals are distributed more often.

Evaluation of the History of Deliveries according to ATC Groups

The trends in individual ATC groups are analysed in the following overviews:

In table 1 we show the volumes of distribution by the main ATC groups (for 1 position) for the years 2011 and 2012.

Table 2 contains the list of TOP 10 medicinal products by the main ATC groups (for 7 positions) in the prices of entities of origin.

Table 3 contains the list of TOP 10 medicinal products by the main ATC groups (for 7 positions) in the prices of entities of origin.

Table 4 contains the list of TOP 20 medicinal products by the main ATC groups (for 3 positions) in the prices of entities of origin.

Table 5 contains the list of TOP 20 medicinal products by the main ATC groups (for 3 positions) in the numbers of packs.

In 2012, in its evaluation of deliveries of distributed medicinal products, the Institute has newly focused on a selected group of medicinal products in each quarter and evaluated the long-term trend in this group in detail. In 1Q, the focus was on antihistamines; in 2Q the focus was on the N06D group – treatment of Alzheimer disease; in 3Q the focus was on pharmaceuticals for treatment of diseases associated with acidity disorders and in 4Q the focus was on influenza vaccine. For more detailed information, see the relevant quarters of 2012.

Information Obtained from Reports of Pharmacies on Dispensed Medicinal Products

According to Guideline SUKL LEK-13, version 2, reports from pharmacies on dispensed medicinal products only contain medicinal products dispensed on medical prescription or dispensed within the category without medical prescription with restriction! The processed data contain reports sent from 2,393 pharmacies.

This chart shows the trend in the number of pharmacies reporting according to LEK-13 for the period from 1 January 2012 to 31 December 2012.

This chart shows the financial trends according to LEK-13 for the period from 1 January 2012 to 31 December 2012.

This chart shows the financial volume and the number of DDDs according to the zones of business mark-up according to LEK-13 for the period of the year 2012.

Legend for the Charts

• Total DDDs (million)
• Price zone
• Supplement
• Finances without the BMU (business mark-up) and VAT (bn)
• ATC code
• Drug code
• Increase/decrease (%)
• ATC name
• Name of the drug
• Number of packs (million)
• Number of reimbursable medicinal products
• Number of SUKL codes
• Number of pharmacies
• Number of marketed medicinal products
• Number of medicinal products with marketing authorisation
• Position
• Year
• Year.month
• Reimbursement from MI (medical insurance)
• Eligible supplementary payment (million)